Their potential of the tracers for prostate cancer imaging was evaluated by an in vitro competition binding assay, PET imaging, and ex vivo biodistribution studies in preclinical PSMA-expressing LNCaP and FAP-expressing HEK293T:hFAP tumor models in mice. Here, FAP is linked to prostate carcinoma.